N/A
Completed N=1,099
Safety and Efficacy Study of Bimatoprost, Latanoprost, and Travoprost in Patients With Elevated Intraocular Pressure (IOP) and Open-angle Glaucoma (OAG)
Source: ClinicalTrials.gov NCT00716742 ↗Enrolled (actual)
1,099
Serious AEs
1.2%
Results posted
Jan 2012
Primary outcomePrimary: Change From Baseline in Bilateral Intraocular Pressure (IOP) at One Year — 20.8; 20.3; 20.6; -4.8 Millimeters of mercury (mmHg)
Summary
To investigate the effectiveness of the newer IOP-lowering therapies, as prescribed in normal clinical practice, in larger patient numbers. Patients will be assessed at baseline, at each follow-up visit (follow-up visits are variable as per physician discretion) and at final follow-up visit.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change From Baseline in Bilateral Intraocular Pressure (IOP) at One Year |
20.8; 20.3; 20.6; -4.8; -4.3; -4.3 | — |
Eligibility Criteria
Inclusion Criteria
- A diagnosis of Primary Open-Angle Glaucoma or Ocular Hypertension newly diagnosed OR presenting with insufficiently controlled IOP on current medication (in the opinion of the treating physician)
- Patient is having both eyes treated
Exclusion Criteria
- Contraindications per product labelling will apply.
- Patients with any ophthalmic co-morbidity with an influence on visual field deterioration or optic nerve head damage.
Data sourced from ClinicalTrials.gov (NCT00716742). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.